Radioiodine therapy in benign and malignant thyroid disorders

Year 2012, , 353 - 361, 07.05.2013

Murathan Şahin , Sibel Uçak Semirgin

https://doi.org/10.5835/jecm.omu.29.s4.025

Abstract

Radioiodine therapy has been an accepted treatment modality of the benign and malignant thyroid disorders. It can be used for the ablation of the hyperfunctioning tissue or postthyroidectomy remnant and treatment of the iodine avid metastases. It is the simplest and safest method of therapy in addition to the effectiveness for most patients.

Keywords

Thyroid cancer, Graves’disease, Solitary toxic nodule, Toxic multinodular goiter, Non-toxic multinodular goiter, Radioiodine theraphy

Benign ve malign tiroit hastalıklarında radyoaktif iyot tedavisi

Abstract

Radyoaktif iyot tedavisi benign ve malign tiroit hastalıklarında kullanılan bir tedavi yöntemidir. Hiperfonksiyonel odakların ve tiroidektomi sonrası rezidü dokunun ablasyonu veya iyot yakalama yeteneğinde olan metastazların tedavisinde kullanılabilmektedir. Genel olarak basit, emniyetli ve efektif bir yöntem olarak kabul edilmektedir.

Keywords

Tiroit kanseri, Graves hastalığı, Otonom toksik nodül, Toksik multinodüler guatr, Nontoksik multinodüler guatr, Radyoaktif iyot tedavisi

References

• Bachmann, J., Kobe, C., Bor, S., Rahlff, I., Dietlein, M., Schicha, H., Schmidt, M., 2009. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl. Med. Commun. 30, 466-471.
• Bahn, R.S., Burch, H.B., Cooper, D.S., Garber, J.R., Greenlee, M.C., Klein, I., Laurberg, P., McDougall, I.R., Montori, V.M., Rivkees, S.A., Ross, D.S., Sosa, J.A., Stan, M.N., 2011. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 21, 593-647.
• Bhattacharyya, N., Chien, W., 2006. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann. Otol. Rhinol. Laryngol. 115, 607-610.
• Bal, C.S., Kumar, A.., Pant, G.S., 2004. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J. Clin. Endocr. Metab. 89, 1666-1673.
• Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Taylor, P.K., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., Curro, N., Daumerie, C., Kahaly, G.J., Krassas, G.E., Lane, C.M., Lazarus, J.H., Marino, M., Nardi, M., Neoh, C., Orgiazzi, J., Pearce1, S., Pinchera, A., Pitz, S., Salvi, M., Sivelli, P., Stahl, M., Arx, G.V., Wiersinga, W.M., 2008. Consensus statement of the European Group on Graves' orbi- topathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158, 273-285.
• Biermann, K., Biersack, H.J., Sabet, A., Janzen, V. 2011. Alternative therapeutic approaches in the treatment of primary and secondary dedif- ferentiated and medullary thyroid carcinoma. Semin. Nucl. Med. 41, 139-148
• Canadas, V., Vilar, L., Moura, E., Brito, A., Castellar, E., 2007. Evaluation of radioiodine therapy with fixed doses of 10 and 15mCi in patients with Graves’ disease. Arq. Bras. Endocrinol. Metab. 51, 1069-1076.
• Chianelli, M., Todino, V., Graziano, F., Panunzi, C., Pace, D., Guglielmi, R., Signore, A., Papini, E., 2009. Low dose (2.0 GBq; 54 mCi) radioio- dine postsurgical remnant ablation in thyroid cancer: Comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur. J. Endocrinol. 160, 431-436.
• Clarke, S.E.M., 1991. Radionuclide theraphy of the thyroid. Eur. J. Nucl. Med. 18, 984-991.
• Collier, A., Gosh, S., Hair, M., Malik, I., McGarvie, J., 2009. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones. 8, 273-278.
• Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Mazzaferri, E.L., McIver, B., Pacini, F., Schlumberger, M., Sherman, S.I., Steward, D.L., Tuttle, R.M., 2009. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19, 1-48.
• Durante, C., Haddy, N.,Baudin, E., Leboulleux, S., Hartl, D., Travagli, J.P., Caillou, B., Richard, M., Lumbroso, J.D., De Vathaire, F., Schlum- berger, M., 2006. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J. Clin. Endocr. Metab. 91, 2892-2899.
• Elgazzar, A.H., Al-Bader, A., 2006. Basis of therapeutic nuclear medicine. In The Pathophysiologic Basis of Nuclear Medicine. A.H. Elgazzar, ed., 2nd edition, Springer-Verlag, Berlin, Heidelberg, New York, pp 521-539.
• Gupta, S.K., McGrath, S., Rogers, K., Attia, J., Lewis, G., Viswanathan, S., Saul, M., Allen, L., 2010. Fixed dose radioiodine for the treatment of hyperthyroidism: Outcome and its predictors. Intern. Med. J. 40, 854-857.
• Harbert, J.C., Robertson, J.S., Held, K.D., 1987. Nuclear Medicine Theraphy. Thieme, New York.
• Henkin, R.E., Del Rowe, J.D., Grigsby, P.W., Hartford, A.C., Jadvar, H., Macklis, R.M., Parker, J.A., Wong, J.Y., Rosenthal, S.A., 2011. ACR- ASTRO Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Clin. Nucl. Med. 36, 72-80.
• Hertz, S., Roberts, A., 1942. Radioactive iodineas indicator in thyroid physiology: Use of radioactive iodine in differential diagnosis of 2 types of Grave’s Disease. J. Clin. Invest. 21, 31-32.
• Huysmans, D.A., Corstens, F.H., Kloppenborg, P.W., 1991. Long-term follow up in toxic solitary autonomous thyroid nodules treated with ra- dioactive iodine. J. Nucl. Med. 32, 27-39.
• Iagraru, A., McDougall, I.R., 2007. Treatment of thyrotoxicosis. J. Nucl. Med. 48, 379–389.
• Iyer, N.G., Morris, L.G.T., Tuttle, R.M., Shaha, A.R., Ganly. I., 2011. Rising incidence of second cancers in patients with low-risk (T1N0) thy- roid cancer who receive radioactive iodine therapy. Cancer. 117, 4439-4446.
• Kebebew, E., Lindsay, S., Clark, O.H., Woeber, K.A., Hawkins, R., Greenspan, F.S., 2009. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroidology. 19, 953-956.
• Kowalsky, R.J., Perry, J.R., 1987. Radipharmaceuticals in Nuclear Medicine Practice. Appleton and Lange, Connecticut. 181-210.
• Leslie, W.D., Ward, L., Salamon, E.A., Ludwıg, S., Rowe, R.C., Cowden, E.A., 2003. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J. Clin. Endocr. Metab. 88, 978-983.
• Luster, M., Clarke, S.E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W.J.G., Tennvall, J., Bombardieri, E., 2008. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging. 35, 1941-1959.
• Ma, C., Xie, J., Kuang, A., 2005. Is empiric I-131 therapy justified for patients with positive thyroglobulin and negative I-131 whole body scan- ning results? J. Nucl. Med. 46, 1164-1170.
• Maxon, H.R., Englaro, E.E., Thomas, S.R., Hertzberg, V.S., Hinnefeld, J.D., Chen, L.S., Smith, H., Cummings, D., Aden, M.D., 1992. Radioio- dine-131 therapy for well-differentiated thyroid cancer: A quantitative radiation dosimetric approach-Outcome and validation in 85 patients. J. Nucl. Med. 33, 1132-1137.
• Maxon, H.R., Smith, H.S., 1990. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol. Clin. North. Am. 19, 685-718.
• McDougall, R., Lagaru, A., 2011. Thyroid stunning: Fact or fiction? Semin. Nucl. Med. 41,105-112.
• Meier, D.A., Dworkin, H.J., Bender, J.M., 2006. Therapy for hyperthyroidism. In Nuclear Medicine, Vol. 2, R.E. Henkin, ed. 2nd edition. Mosby, Philadelphia, pp. 1567-1575.
• Morris, J.C., 2010. Resveratrol, thyroid cancer and iodide: Drink up? Thyroid. 20, 125-126.
• Nostrand, D.V., Aiken, M., Atkins, F., Moreau, S., Garcia, C., Acio, E., Burman, K., Wartofsky, L., 2009. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 19, 849-855.
• Nygaard, B., Hegedus, L., Nielsen, K.G., Ulriksen, P., Hansen, J.M., 1999. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin. Endocrinol. 50,197-202.
• Pacini, F., Castagna, M.G., Brilli, L., Pentheroudakis, G., 2010. Tyhroid cancer: ESMO Clinical Practice Guidelines for diagnosis. Treatment and follow-up. Ann. Oncol. 21, 214-219.
• Peters, H., Fischer, C., Bogner, U., Reiners, C., Schleusener, H., 1995. Radioiodine therapy of Graves’ hyperthyroidism: Standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur. J. Clin. Invest. 25, 186–193.
• Pitoia, F., Ward, L., Wohllk, N., Friguglietti, C., Tomimori, E., Gauna, A., Camargo, R., Vaisman, M., Harach,R., Munizaga, F., Corigliano, S., Pretell, E., Niepomniszcze, H., 2009. Recommendations of the Latin American Thyroid Society on diagnosis and management of differenti- ated thyroid cancer. Arq Bras Endocrinol Metab. 53, 884-897.
• Porterfield J.R., Thompson, G.B., Farley, D.R., Grant, C.S., Richards, M.L., 2008. Evidence-based Management of Toxic Multinodular Goiter (Plummer’s Disease). World J. Surg. 32,1278–1284.
• Radyasyon güvenliği yönetmeliğinde değişiklik yapılmasına dair yönetmelik, Madde 7. T.C. Resmi Gazete, 25598, 29 Eylül 2004.
• Read, C.H., Tansey, M.J., Menda, Y., 2004. A 36-year retrospective analysis of the efficacy and safety of radioiodine in treating young Graves' patients. J. Clin. Endocr. Metab. 89, 4229-4233.
• Reiners, C., Dietlein, M., Luster, M., 2008. Radio-iodine therapy in differentiated thyroid cancer: Indications and procedures. Best Pract Res Clin Endocrinol Metab. 22, 989-1007.
• Ron, E., Doody, M.M., Becker, D.V., Brill, A.B., Curtis, R.E., Goldman, M. B., Haris, B.S.H., Hoffman, D.A., McConahey,W.M., Maxon, H.R., Preston-Martin, S., Warshauer, M.E., Wong, F.L., Boice, J.D., 1998. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 280, 347-355.
• Ross, D.S., Ridgway, E.C., Daniels, G.H., 1984. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann. Intern. Med. 101, 488-490.
• Rubino C., de Vathaire, F., Dottorini, M.E., Hall, P., Schvartz, C., Couette J.E., Dondon, M.G., Abbas, M.T., Langlois, C., Schlumberger, M., 2003. Second primary malignancies in thyroid cancer patients. Br. J. Cancer. 89, 1638-1644.
• Salvatori, M., Luster, M., 2010. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 37,821-828.
• Silberstein, E.B., 2011. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: The TENIS syndrome. Semin. Nucl. Med. 41, 113-120.
• Silberstein, E.B., 2006. The treatment of thyroid malignant neoplasms. In Nuclear Medicine, Vol. II , R.E. Henkin, ed., 2nd edition, Mosby Elsevier, Philadelphia, pp.1576-1587.
• Stokkel, M.P.M., Handkiewicz, J., Lassman, M., Dietlein, M., Luster, M., 2010. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 37, 2218-2228.
• Tallstedt, L., Lundell, G., Tİrring, O., Wallin, G., Ljunggren, J.G., Blomgren, H., Taube, A., 1992. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N. Engl. J. Med. 326, 1733-1738.
• Tuttle, R.M., Ball, D.W., Byrd, D., Dilawari, R.A., Doherty, G.M., Duh, Q.Y., Ehya, H., Farrar, W.B., Haddad, R.I., 2012. The NCCN Thy- roid Carcinoma Panel Members. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Thyroid Carcinoma V.2.2012. www.nccn.org. Date: 14/01/2012.
• Tzavara, I., Tzanela, M., Vlassopoulou, B., Kouyiomoutzakis, G., Kyriazopoulou, V., Alevizaki, C., Thalassinos, N.C., 2002. Long term thyroid function after (131)I treatment for toxic adenoma. Hormones. 1, 99-103.
• Von Hofe, S.E., Dorfman, S.G., Carretta, R.F., Young, R.L., 1978. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J. Nucl. Med. 19, 180-184.
• Wartofsky, L., Glinoer, D., Solomon, B., Nagatakı, S., Lagasse, R., Nagayama, Y., Izumı, M., 1991. Differences and similarities in the diagnosis and treatment of Graves disease in Europa, Japan and the United States. Thyroid. 1, 129-135.
• Yano, Y., Sugino, K., Akaishi, J., Uruno, T., Okuwa, K., Shibuya, H., Kitagawa, W., Nagahama, M., Ito, K., 2011. Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy. Ann. Nucl. Med. 25, 749– 754.
• Zakavi, S.R., Mousavi, Z., Davachi, B., 2009. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl. Med. Commun. 30, 169-175.
• Zimmermann, R., 2007. Nuclear Medicine, Radioactivity for Diagnosis and Therapy. EDP Sciences, Cedex. 7-8.